Valuation: Kinarus Therapeutics Holding AG

Market Cap 4.72M 5.88M 5.04M 4.32M 8.1M 563M 8.21M 55.72M 21.73M 283M 22.1M 21.62M 936M P/E 2022
-0.23x
P/E 2023 -0.01x
Enterprise Value 4.71M 5.87M 5.03M 4.31M 8.09M 562M 8.19M 55.62M 21.69M 282M 22.05M 21.57M 934M EV / Sales 2022
4,318,722x
EV / Sales 2023 -
Free-Float
-
Yield 2022 *
-
Yield 2023 -
1 day-2.01%
Current month+20.91%
Current year+20.91%
3 years 0.9
Extreme 0.895999
35.84
5 years 0.9
Extreme 0.895999
230.27
10 years 0.9
Extreme 0.895999
230.27

Financials

2022 2023
Net sales 3.34 4.16 3.57 3.05 5.73 398.24 5.81 39.41 15.37 200.05 15.63 15.29 661.69 -
Net income -34.73M -43.33M -37.12M -31.79M -59.67M -4.15B -60.45M -410M -160M -2.08B -163M -159M -6.89B -49.38M -61.61M -52.77M -45.2M -84.83M -5.89B -85.95M -583M -228M -2.96B -231M -226M -9.79B
Net Debt 1.66M 2.07M 1.77M 1.52M 2.85M 198M 2.89M 19.59M 7.64M 99.43M 7.77M 7.6M 329M -9K -11.23K -9.62K -8.24K -15.46K -1.07M -15.67K -106K -41.47K -540K -42.16K -41.25K -1.79M
Logo Kinarus Therapeutics Holding AG
Kinarus Therapeutics Holding AG is a Switzerland-based Company that operates as a biopharmaceutical industry engaged in diseases treatment. The Company conducts its work within clinical-stage area and its activities include discovery, examination and development of medicines that are intended for the treatment of viral, respiratory, and ophthalmic diseases. Kinraus therapeutic drug is patent protected KIN001 which is a combination of pamapimod and pioglitazone. KIN0001 offers oral, long-term treatment of diseases with severe impact on the comfort of living.
Employees
-
Sector
-
Date Price Change Volume
21/08/26 CHF 19.50 -2.01% 1,420
20/08/26 CHF 19.90 -0.25% 783
19/08/26 CHF 19.95 -0.25% 1,165
18/08/26 CHF 20.00 +10.50% 1,697
17/08/26 CHF 18.10 +0.56% 46
  1. Stock Market
  2. Stocks
  3. CURE Stock